[go: up one dir, main page]

MX2022006278A - Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos. - Google Patents

Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos.

Info

Publication number
MX2022006278A
MX2022006278A MX2022006278A MX2022006278A MX2022006278A MX 2022006278 A MX2022006278 A MX 2022006278A MX 2022006278 A MX2022006278 A MX 2022006278A MX 2022006278 A MX2022006278 A MX 2022006278A MX 2022006278 A MX2022006278 A MX 2022006278A
Authority
MX
Mexico
Prior art keywords
diagnosis
prevention
treatment
malignant tumours
salmon proteins
Prior art date
Application number
MX2022006278A
Other languages
English (en)
Inventor
Cusani Alberto Bartorelli
Original Assignee
Cusani Alberto Bartorelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cusani Alberto Bartorelli filed Critical Cusani Alberto Bartorelli
Publication of MX2022006278A publication Critical patent/MX2022006278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se describen proteínas de salmón UK 114 para uso en el tratamiento, diagnóstico y prevención de tumores malignos.
MX2022006278A 2019-11-26 2020-11-23 Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos. MX2022006278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102019000022203A IT201900022203A1 (it) 2019-11-26 2019-11-26 Proteine uk 114 da salmone per uso nella terapia, nella diagnostica e nella prevenzione di neoplasie maligne
PCT/EP2020/083069 WO2021105059A1 (en) 2019-11-26 2020-11-23 Uk 114 salmon proteins for use in the treatment, diagnosis and prevention of malignant tumours

Publications (1)

Publication Number Publication Date
MX2022006278A true MX2022006278A (es) 2022-08-15

Family

ID=70009105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006278A MX2022006278A (es) 2019-11-26 2020-11-23 Proteinas de salmon uk 114 para uso en el tratamiento, diagnostico y prevencion de tumores malignos.

Country Status (8)

Country Link
US (1) US20230000946A1 (es)
EP (1) EP4065154A1 (es)
JP (1) JP2023504241A (es)
CN (1) CN114761034A (es)
CA (1) CA3159292A1 (es)
IT (1) IT201900022203A1 (es)
MX (1) MX2022006278A (es)
WO (1) WO2021105059A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300004776A1 (it) * 2023-03-14 2024-09-14 Giovanni Bussolati Deaminasi intermedia reattiva a (reactive intermediate deaminase a, rida) per uso nella prevenzione e/o trattamento della cachessia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270618B (it) 1994-07-14 1997-05-07 Zetesis Spa Proteine ad attivita' antitumorale
IT1276860B1 (it) * 1994-11-04 1997-11-03 Zetesis Spa Anticorpi naturali contro proteine allogeniche e xenogeniche e metodi per la loro determinazione
US20010014471A1 (en) * 1999-04-15 2001-08-16 Vytautas Naktinis Recombinant protein and its use in therapy and diagnostics
IT201600127428A1 (it) * 2016-12-16 2018-06-16 Cusani Alberto Bartorelli Nuova proteina ricombinante uk 114 in forma stabile polimerica per uso nella terapia, nella diagnostica e nella prevenzione di neoplasie maligne

Also Published As

Publication number Publication date
CN114761034A (zh) 2022-07-15
EP4065154A1 (en) 2022-10-05
WO2021105059A1 (en) 2021-06-03
CA3159292A1 (en) 2021-06-03
US20230000946A1 (en) 2023-01-05
IT201900022203A1 (it) 2021-05-26
JP2023504241A (ja) 2023-02-02

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
GEAP202215447A (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
PH12021550152A1 (en) Anti-cd112r compositions and methods
PH12021552856A1 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
CA3055791A1 (en) Treatment methods
WO2017096309A8 (en) Methods of treatment of malignancies
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
SG10201809411PA (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
PH12022551105A1 (en) Tyk2 pseudokinase ligands
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2022002699A (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
EP4585273A3 (en) Mechanism of resistance to bet bromodomain inhibitors
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
PH12019502197A1 (en) Macrocyclic compound and uses thereof
MX382778B (es) Metodos para tratar cancer pancreatico
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2022000263A (es) Nuevos antigenos y metodos contra el cancer.
MX2021015765A (es) Nuevos antigenos y metodos contra el cancer.
WO2020079448A9 (en) Novel cancer antigens and methods